

OFFICE OF THE SECRETARY OF STATE

LAVONNE GRIFFIN-VALADE
SECRETARY OF STATE

CHERYL MYERS
DEPUTY SECRETARY OF STATE
AND TRIBAL LIAISON



ARCHIVES DIVISION

STEPHANIE CLARK
DIRECTOR

800 SUMMER STREET NE
SALEM, OR 97310
503-373-0701

TEMPORARY ADMINISTRATIVE ORDER
INCLUDING STATEMENT OF NEED & JUSTIFICATION

BP 25-2024

CHAPTER 855

BOARD OF PHARMACY

FILED

03/04/2024 3:17 PM
ARCHIVES DIVISION
SECRETARY OF STATE
& LEGISLATIVE COUNSEL

FILING CAPTION: Modifies Coronavirus-19 Protocol in Protocol Compendium

EFFECTIVE DATE: 03/04/2024 THROUGH 08/30/2024

AGENCY APPROVED DATE: 03/04/2024

CONTACT: Rachel Melvin

971-673-0001

pharmacy.rulemaking@bop.oregon.gov

800 NE Oregon St., Suite 150

Portland, OR 97232

Filed By:

Rachel Melvin

Rules Coordinator

NEED FOR THE RULE(S):

Temporarily updates the Coronavirus-19 protocol in the protocol compendium to reflect the latest recommendations by the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP). The update also incorporates information on the new single-dose glass syringe formulation of the Comirnaty COVID-19 vaccine by Pfizer.

JUSTIFICATION OF TEMPORARY FILING:

Failure to update the coronavirus-19 vaccine protocol in OAR 855-115-0345 will result in pharmacists utilizing the protocol to not be able to administer the vaccine according to the latest recommendations. This could leave individuals vulnerable to COVID-19 and its serious complications. Delayed updates could lead to inefficiencies in vaccine administration and potentially overwhelm other healthcare providers.

DOCUMENTS RELIED UPON, AND WHERE THEY ARE AVAILABLE:

Coronavirus_19 https://www.oregon.gov/pharmacy/Documents/PrevCare_IMZ_Coronavirus_19.pdf

AMEND: 855-115-0345

RULE SUMMARY: Temporarily amends OAR 855-115-0345 by revising the Coronavirus 19 vaccine protocol in the protocol compendium.

CHANGES TO RULE:

855-115-0345

Services: Prescribing - Protocol Compendium

A Pharmacist may prescribe, according to OAR 855-115-0330 and OAR 855-115-0335, FDA-approved drugs and devices listed in the following compendium, pursuant to a statewide drug therapy management protocol. ¶

(1) Continuation of therapy including emergency refills of insulin (v. 06/2023)¶

(2) Conditions¶

(a) Cough and cold symptom management¶

- (A) Pseudoephedrine (v. 06/2021);¶¶
- (B) Benzonatate (v. 06/2021);¶¶
- (C) Short-acting beta agonists (v. 06/2021);¶¶
- (D) Intranasal corticosteroids (v. 06/2021);¶¶
- (b) Vulvovaginal candidiasis (VVC) (v. 06/2021);¶¶
- (c) COVID-19 Antigen Self-Test (v. 12/2021);¶¶
- (3) Preventative care¶¶
- (a) Emergency Contraception (v. 06/2021);¶¶
- (b) Male and female condoms (v. 06/2021);¶¶
- (c) Tobacco Cessation, NRT (Nicotine Replacement Therapy) and Non-NRT (v. 06/2022);¶¶
- (d) Travel Medications (v. 06/2023);¶¶
- (e) HIV Post-exposure Prophylaxis (PEP) (v. 06/2023);¶¶
- (f) HIV Pre-exposure Prophylaxis (PrEP) (v.06/2023); and¶¶
- (g) Contraception (v. 06/2023); and¶¶
- (h) Vaccines:¶¶
- (A) Standard Protocol for All Vaccines: Cover Page & Assessment and Treatment Care Pathway (v. 2/2024); ¶¶
- (B) Standard Protocol for All Vaccines: Managing Adverse Reactions (v. 2/2024); ¶¶
- (C) Cholera (v. 2/2024); ¶¶
- (D) Coronavirus 2019 (v. 3/2024); ¶¶
- (E) Haemophilus Influenza type b (v. 2/2024);¶¶
- (F) Hepatitis A containing vaccines (v. 2/2024); ¶¶
- (G) Hepatitis B containing vaccines (v. 2/2024); ¶¶
- (H) Human Papillomavirus (v. 2/2024); ¶¶
- (I) Influenza - Inactivated Influenza Vaccines and Recombinant Influenza Vaccines 2023-24 (v. 2/2024); ¶¶
- (J) Influenza - Live Attenuated Influenza Vaccine 2023-24 (v. 2/2024); ¶¶
- (K) Japanese Encephalitis (v. 2/2024); ¶¶
- (L) Meningococcal containing vaccines (v. 2/2024); ¶¶
- (M) Measles Mumps & Rubella containing vaccines (v. 2/2024); ¶¶
- (N) Pneumococcal (v. 2/2024); ¶¶
- (O) Polio (v. 2/2024);¶¶
- ¶¶
- (P) Rabies (v. 2/2024); ¶¶
- (Q) Respiratory Syncytial Virus (v. 2/2024);¶¶
- (R) Tetanus Diphtheria containing vaccines (v. 2/2024);¶¶
- (S) Typhoid (v. 2/2024); ¶¶
- (T) Varicella containing vaccines (v. 2/2024);¶¶
- (U) Yellow fever (v. 2/2024); and¶¶
- (V) Zoster (v. 2/2024).¶¶

[Publications: Publications referenced are available from the agency.]

Statutory/Other Authority: ORS 689.205

Statutes/Other Implemented: ORS 689.645, ORS 689.649, ORS 689.689